Epithelial ovarian cancer
References

1 Scottish Cancer Intelligence Unit. Trends in cancer survival in Scotland 1971-1995. Edinburgh: Information and Statistics Division; 2000. [cited 2 Sep 2003]. Available from url: http://www.isdscotland.org/isd/files/trends_1971-95.pdf [Back]

2 Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991;49(1):61-5. [Back]

3 Information and Statistics Division. Cancer of the ovary (ICD-10 C56). Lifetime risk of developing cancer (up to the age of 90), Scotland 1994 - 1998. Edinburgh: The Division; 2002. [cited 2 Sep 2003]. Available from url http://www.isdscotland.org/isd/files/cancer_ovary_risk.xls [Back]

4 Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94(18):1358-65. [Back] [section 1.1] [section 2.2.2]

5 Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997;349(9045):113-7. [Back]

6 Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999;106(11):1130-6. [Back] [section 1.1] [section 4.4]

7 Gatta G, Lasota MB, Verdecchia A. Survival of European women with gynaecological tumours, during the period 1978-1989. Eur J Cancer 1998;34(14):2218-25. [Back]

8 Pecorelli S, Odicino F, Maisonneuve P, Creasman W, Shepherd J, Sideri M, et al. FIGO staging of gynecologic cancer. Carcinoma of the ovary. London; The International Federation of Gynecology and Obstetrics:1998. [cited 2 Sep 2003]. Available from url: http://www.figo.org/content/PDF/staging-booklet.pdf [Back] [section 1.3] [annex 1]

9 Haites NE, Black R, Campbell H, Clark C, Davidson R, Davis J, et al. Guidelines for regional genetic centres on the implementation of genetic services for breast, ovarian and colorectal cancer families in Scotland. CME Journal of Gynaecologic Oncology 2000:5(3);291-307. [Back]

10 Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health Technol Assess 1998;2(2):1-84. [cited 2 Sep 2003]. Available from url: http://www.hta.nhsweb.nhs.uk/ProjectData/3_project_record_published.asp?PjtId=972[Back]

11 Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998;105(5):493-9. [Back]

12 Morrison PJ, Hodgson SV, Haites NE, editors. Familial breast and ovarian cancer: genetics, screening and management. Cambridge: Cambridge University Press; 2002. [Back]

13 Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91(15):1310-6. [Back]

14 Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81(2):214-8. [Back]

15 Hyland F, Kinmonth AL, Marteau TM, Griffin S, Murrell P, Spiegelhalter D, et al. Raising concerns about family history of breast cancer in primary care consultations: prospective, population based study. Women’s Concerns Study Group. BMJ 2001;322(7277):27-8. [Back]

16 Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353(9160):1207-10. [Back]

17 Fry A, Campbell H, Gudmunsdottir H, Rush R, Porteous M, Gorman D, et al. GPs’ views on their role in cancer genetics services and current practice. Fam Pract 1999;16(5):468-74. [Back]

18 Escher M, Sappino AP. Primary care physicians’ knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann Oncol 2000;11(9):1131-5. [Back]

19 Rose PW, Watson E, Yudkin P, Emery J, Murphy M, Fuller A, et al. Referral of patients with a family history of breast/ovarian cancer-GPs’ knowledge and expectations. Fam Pract 2001;18(5):487-90. [Back]

20 Bankhead C, Emery J, Qureshi N, Campbell H, Austoker J, Watson E. New developments in genetics-knowledge, attitudes and information needs of practice nurses. Fam Pract 2001:18(5);475-86. [Back]

21 Walter FM, Kinmonth AL, Hyland F, Murrell P, Marteau TM, Todd C. Experiences and expectations of the new genetics in relation to familial risk of breast cancer: a comparison of the views of GPs and practice nurses. Fam Pract 2001;18(5):491-4. [Back]

22 Elwyn G, Iredale R, Gray J. Reactions of GPs to a triage-controlled referral system for cancer genetics. Fam Pract 2002;19(1):65-71. [Back]

23 Watson E, Clements A, Yudkin P, Rose P, Bukach C, Mackay J, et al. Evaluation of the impact of two educational interventions on GP management of familial breast/ovarian cancer cases: a cluster randomised controlled trial. Br J Gen Pract 2001;51(471):817-21. [Back]

24 Wonderling D, Hopwood P, Cull A, Douglas F, Watson M, Burn J, et al. A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics. Br J Cancer 2001;85(2):166-70. [Back]

25 NHS Executive. Guidance on commissioning cancer services: improving outcomes in gynaecological cancer: the research evidence. London: The Executive; 1999. [Back]

26 Taylor L, Schwarz H. Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay. J Immunol Methods 2001;255(1-2):67-72. [Back]

27 Karlan BY, Baldwin RL, Lopez-Luevanos E, Raffel LJ, Barbuto D, Narod S, et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999;180(4):917-28. [Back]

28 Moller P, Borg A, Heimdal K, Apold J, Vallon-Christersson J, Hovig E, et al. The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series. Eur J Cancer 2001;37(8):1027-32. [Back] [section 2.3] [section 2.5]

29 Erlick Robinson G, Rosen BP, Bradley LN, Rockert WG, Carr ML, Cole DE, et al. Psychological impact of screening for familial ovarian cancer: reactions to intial assessment. Gynecol Oncol 1997:65(2);197-205. [Back]

30 Wardle J, Pernet A, Collins W, Bourne T. False positive results in ovarian cancer: one year followup of psychological status. Psychol Health 1994:10(1);33-40. [Back]

31 Wardle FJ, Collins W, Pernet AL, Whitehead MI, Bourne TH, Campbell S. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst 1993;85(8):653-7. [Back]

32 Audrain J, Schwartz MD, Lerman C, Hughes C, Peshkin BN, Biesecker B. Psychological distress in women seeking genetic counseling for breast-ovarian cancer risk: the contributions of personality and appraisal. Ann Behav Med 1998;19(4):370-7. [Back]

33 Cull A, Fry A, Rush R, Steel CM. Cancer risk perceptions and distress among women attending a familial ovarian cancer clinic. Br J Cancer 2001;84(5):594-9. [Back]

34 Pernet AL, Wardle J, Bourne TH, Whitehead MI, Campbell S, Collins WP. A qualitative evaluation of the experience of surgery after false positive results in screening for familial ovarian cancer. Psycho-oncology 1992;1:217-33. [Back]

35 Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346(21):1609-15. [Back]

36 Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346(21):1616-22. [Back]

37 Hallowell N. A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psycho-Oncology 2000;9(6):486-95. [Back]

38 Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psycho-Oncology 2001;10(3):231-41. [Back]

39 Wagner TM, Moslinger R, Langbauer G, Ahner R, Fleischmann E, Auterith A, et al. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer 2000;82(7):1249-53. [Back]

40 Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S. Symptoms of ovarian cancer. Obstet Gynecol 2001;98(2):212-7. [Back]

41 Flam F, Einhorn N, Sjovall K. Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1988;27(1):53-7. [Back]

42 Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000;89(10):2068-75. [Back]

43 Scottish Cancer Information Unit. Cancer registration statistics Scotland 1986-1995. Edinburgh: Information and Statistics Division; 1998. [Back]

44 Kirwan JM, Tincello DG, Herod JJ, Frost O, Kingston RE. Effect of delays in primary care referral on survival of women with epithelial ovarian cancer: retrospective audit. BMJ 2002;324(7330):148-51. [Back]

45 Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309(45):883-7. [Back]

46 Daoud E, Bodor G. CA-125 concentrations in malignant and nonmalignant disease. Clin Chem 1991;37(11):1968-74. [Back]

47 Sturgeon C. Practice guidelines for tumor markers use in the clinic. Clin Chem 2002;48(8):1151-9. [Back] [section 3.1.2] [section 4.1.5]

48 Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4(1):1-12. [Back]

49 Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 1983;79(1):98-104. [Back]

50 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. B J Obstet Gynaecol 1990;97(10):922-9. [Back]

51 Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996;103(8):826-31. [Back]

52 Morgante G, la Marca A, Ditto A, De Leo V. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol 1999;106(6):524-7. [Back]

53 Aslam N, Tailor A, Lawton F, Carr J, Savvas M, Jurkovic D. Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer. BJOG 2000;107(11):1347-53. [Back]

54 Tailor A, Jurkovic D, Bourne TH, Collins WP, Campbell S. Sonographic prediction of malignancy in adnexal masses using multivariate logistic regression analysis. Ultrasound Obstet Gynecol 1997;10(1):41-7. [Back]

55 Antonic J, Rakar S. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. Anticancer Res 1995;15(4):1527-32. [Back]

56 Tamussino KF, Lim PC, Webb MJ, Lee RA, Lesnick TG. Gastrointestinal surgery in patients with ovarian cancer. Gynecol Oncol 2001;80(1):79-84. [Back]

57 Donato D, Angelides A, Irani H, Penalver M, Averette H. Infectious complications after gastrointestinal surgery in patients with ovarian carcinoma and malignant ascites. Gynecol Oncol 1992;44(1):40-7. [Back]

58 Scottish Intercollegiate Guidelines Network (SIGN). Management of colorectal cancer. Edinburgh: SIGN; 2003. (SIGN publication no. 67). [cited 3 Sep 2003]. Available from url: http://www.sign.ac.uk/guidelines/fulltext/67/index.html [Back] [section 4.1.1] [section 4.1.2]

59 Bass EM, Del Pino A, Tan A, Pearl RK, Orsay CP, Abcarian H. Does preoperative stoma marking and education by the enterostomal therapist affect outcome? Dis Colon Rectum 1997;40(4):440-2. [Back]

60 Park JJ, Del Pino A, Orsay CP, Nelson RL, Pearl RK, Cintron JR, et al. Stoma complications: the Cook County Hospital experience. Dis Colon Rectum 1999;42(12):1575-80. [Back]

61 Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism. Edinburgh: SIGN; 2002. (SIGN publication no. 62). [cited 3 Sep 2003]. Available from url: http://www.sign.ac.uk/guidelines/fulltext/62/index.html [Back]

62 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318(18):1162-73. [Back]

63 Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg 1997;84(6):750-9. [Back]

64 Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77(2):227-31. [Back]

65 Gemer O, Segal S, Kopmar A. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand 2001;80(6):583-5. [Back]

66 Maggino T, Gadducci A. Serum markers as prognostic factors in epithelial ovarian cancer: an overview. Eur J Gynaecol Oncol 2000;21(1):64-9. [Back]

67 Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, et al. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Gynecol Obstet Invest 1999;47(1):52-7. [Back]

68 Scottish Intercollegiate Guidelines Network (SIGN). Antibiotic prophylaxis in surgery. Edinburgh: SIGN; 2000. (SIGN publication no. 45). [cited 3 Sep 2003]. Available from url: http://www.sign.ac.uk/guidelines/fulltext/45/index.html [Back]

69 Yeo EL, Yu KM, Poddar NC, Hui PK, Tang LC. The accuracy of intraoperative frozen section in the diagnosis of ovarian tumors. J Obstet Gynaecol Res 1998;24(3):189-95. [Back]

70 Houck K, Nikrui N, Duska L, Chang Y, Fuller AF, Bell D, et al. Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis. Obstet Gynecol 2000;95:839-43. [Back]

71 Usubutun A, Altinok G, Kucukali T. The value of intraoperative consultation (frozen section) in the diagnosis of ovarian neoplasms. Acta Obstet Gynecol Scand 1998;77(10):1013-6. [Back]

72 Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, et al. Staging laparotomy in early ovarian cancer. JAMA 1983;250(22):3072-6. [Back]

73 Helewa ME, Krepart GV, Lotocki R. Staging laparotomy in early epithelial ovarian carcinoma. Am J Obstet Gynecol 1986;154(2):282-6. [Back]

74 Hand R, Fremgen A, Chmiel JS, Recant W, Berk R, Sylvester J, et al. Staging procedures, clinical management, and survival outcome for ovarian carcinoma. JAMA 1993;269(9):1119-22. [Back]

75 Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Nat Cancer Inst 2003;95(2):113-25. [Back] [section 4.3] [section 5.3]

76 Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International Collaborative Ovarian Neoplasm (ICON) collaborators. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Nat Cancer Inst 2003;95(2):125-32. [Back] [section 4.3] [section 5.3]

77 Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Nat Cancer Inst 2003;95(2):105-12. [Back] [section 4.3] [section 5.3]

78 Zanetta G, Chiari S, Rota S, Bratina G, Maneo A, Torri V, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 1997;104(9):1030-5. [Back]

79 Kottemeier HL. Surgical treatment - conservative surgery. In: Gentil F, Junqueira AC, editors. Ovarian cancer. New York: Springer Verlag 1968. IUCC monograph series no. 11. [Back]

80 Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166(2):504-11. [Back]

81 Voest EE, van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk] as main objectives. Eur J Cancer Clin Oncol 1989;25(4):711-20. [Back]

82 Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1995;16(5):349-56. [Back]

83 Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20(5):1248-59. [Back]

84 Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren A. National survey of ovarian carcinoma. Part V. The impact of physician’s specialty on patients’ survival. Cancer 1993;72(12):3663-70. [Back]

85 Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GR. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101(2):142-6. [Back]

86 van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332(10):629-34. [Back]

87 Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, et al. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study [abstract]. Alexandra (VA): American Society of Clinical Oncology; 2002. [cited 3 Sep 2003]. Available from url: http://www.asco.org/ac/1,1003,_12-002643-00_18-0016-00_19-00802,00.asp[Back]

88 Bristow RE, Lagasse LD, Karlan BY. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. Cancer 1996;78(10):2049-62. [Back] [section 4.6] [section 6]

89 Maughan K, Clarke C. The effect of a clinical nurse specialist in gynaecological oncology on quality of life and sexuality. J Clin Nurs 2001;10(2):221-9. [Back]

90 McArdle JM, George WD, McArdle CS, Smith DC, Moodie AR, Hughson AV, et al. Psychological support for patients undergoing breast cancer surgery: a randomised study. BMJ 1996;312(7034):813-6. [Back]

91 Ambler N, Rumsey N, Harcourt D, Khan F, Cawthorn S, Barker J. Specialist nurse counsellor interventions at the time of diagnosis of breast cancer: comparing ‘advocacy’ with a conventional approach. J Adv Nurs 1999;29(2):445-53. [Back]

92 Clinical Standards Board for Scotland. Clinical standards: gynaecological (ovarian) cancer. Edinburgh: The Board; 2001. [cited 3 Sep 2003]. Available from url: http://www.clinicalstandards.org/pdf/finalstand/Ovarian_Cancer.pdf [Back]

93 Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer 2001;85(7):944-52. [Back]

94 Flynn PM, Paul J, Cruickshank DJ, Scottish Gynaecological Cancer Trials Group. Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? Gynecol Oncol 2002;86(3):354-7. [Back]

95 Ovarian cancer: screening, treatment, and followup. NIH Consens Statement 1994;12(3):1-29. [cited 3 Sep 2003]. Available from url: http://odp.od.nih.gov/consensus/cons/096/096_intro.htm [Back]

96 Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357(9251):176-82. [Back]

97 Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71(3):431-6. [Back]

98 Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999;72(1):93-9. [Back]

99 Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. [Back] [section 5.5.1] [section 5.5.2]

100 ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet 1998;352(9140):1571-6. [Back] [section 5.5.1] [section 5.5.5]

101 Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18(17):3084-92. [Back] [section 5.5.2] [section 5.5.3]

102 Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000;18(1):106-15. [Back]

103 Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92(9):699-708. [Back] [section 5.5.3] [section 5.5.4]

104 National Institute for Clinical Excellence. Guidance on the use of paclitaxel in the treatment of ovarian cancer. London: The Institute; 2003. Technology appraisal no. 55. [cited 3 Sep 2003]. Available from url: http://www.nice.org.uk/pdf/55_Paclitaxel_ovarianreviewfullguidance.pdf [Back]

105 International Collaborative Ovarian Neoplasm Group. Paclitaxal plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360(9332):505-15. [Back]

106 McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6. [Back]

107 West RJ, Zweig SF. Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gynaecol Oncol 1997;18(5):343-8. [Back]

108 Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989;59(4):650-3. [Back]

109 Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002;20(5):1232-7. [Back]

110 Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR2.2 trial. Lancet 2003;361(9375):2099-106. [Back]

111 ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15(6):2183-93. [Back]

112 Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312-22. [Back]

113 National Institute for Clinical Excellence. Guidance on the use of pegylated liposomal doxorubicin hydrochloride (PLDH) for the treatment of advanced ovarian cancer. London: The Institute; 2002. Technology appraisal no. 45. [cited 3 Sep 2003]. Available from url: http://www.nice.org.uk/pdf/Fullguidance-PDF-ovariancancer.pdf [Back]

114 Health Technology Board for Scotland. NICE technology appraisal guidance - no. 45. Glasgow: The Board; 2002. [cited 3 Sep 2003]. Available from url: http://www.nhshealthquality.org/nhsqis/qis_Publications3.jsp?pContentID=942[Back]

115 Williams CJ, Simera I. Tamoxifen for relapse of ovarian cancer (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. [Back]

116 Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998;25(3 Suppl 7):2-6. [Back]

117 Quirt I, Micucci S, Moran LA, Pater J, Browman G. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee. Cancer Prev Control 1997;1(3):241-8. [Back]

118 Seidenfeld J, Aronson N, Piper M, Flamm CR, Hasselblad V. Ziegler KM. Uses of epoetin for anemia in oncology. Rockville (MD): Agency for Healthcare Research and Quality; 2001. AHRQ publication no. 01-E009. [cited 3 Sep 2003]. Available from url: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.43994[Back]

119 Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335(26):1950-5. [Back]

120 Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19(4):1001-7. [Back]

121 Armstrong DK, Bundy BN, Baergen R, Lele SB, Copeland LJ, Walker J, et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172) [abstract]. Alexandra (VA): American Society of Clinical Oncology; 2002. [cited 3 Sep 2003]. Available from url: http://www.asco.org/ac/1,1003,_12-002640-00_18-0016-00_19-00803,00.asp[Back]

122 Joint Council for Clinical Oncology. Quality control in cancer chemotherapy: managerial and procedural aspects. London: The Council; 1994. [Back]

123 Royal College of Radiologists’ Clinical Oncology Information Network. Guidelines for cytotoxic chemotherapy in adults. A document for local expert groups in the United Kingdom preparing chemotherapy policy documents. Clin Oncol (R Coll Radiol) 2001;13(1):s209-48. [cited 3 Sep 2003]. Available from url: http://www.rcr.ac.uk/upload/ChemotherapyGuideline2001.pdf [Back]

124 Scottish Executive. Guidelines for the use of cytotoxic chemotherapy in the clinical environment. Edinburgh: The Executive; 2001. NHS HDL(2001)13. [cited 3 Sep 2003]. Available from url: http://www.show.scot.nhs.uk/sehd/mels/HDL2001_13.htm [Back]

125 Lutgendorf SK, Anderson B, Rothrock N, Buller RE, Sood AK, Sorosky JI. Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. Cancer 2000;89(6):1402-11. [Back]

126 Montazeri A, McEwen J, Gillis CR. Quality of life in patients with ovarian cancer: current state of research. Support Care Cancer 1996;4(3):169-79. [Back]

127 Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001;19(5):1266-74. [Back]

128 Guidozzi F. Living with ovarian cancer. Gynecol Oncol 1993;50(2):202-7. [Back]

129 Kornblith AB, Thaler HT, Wong G, Vlamis V, Lepore JM, Loseth DB, et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995;59(2):231-42. [Back]

130 Carter JR, Chen MD, Fowler JM, Carson LF, Twiggs LB. The effect of prolonged cycles of chemotherapy on quality of life in gynaecologic cancer patients. J Obstet Gynaecol Res 1997;23(2):197-203. [Back]

131 Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progresion of ovarian carcinoma during follow-up according to CA 125: a north Thames Ovary Group Study. Ann Oncol 1996;7(4):361-4. [Back]

132 Van der Berg ME, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990;1(4):301-2. [Back]

133 Low RN, Saleh F, Song SY, Shiftan TA, Barone RM, Lacey CG, Goldfarb PM. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination - a longitudinal study. Radiology 1999;211(2):519-28. [Back]

134 Zanetta G, Rota S, Lissoni A, Meni A, Brancatelli G, Buda A. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynaecol Oncol 2001;81(1):63-6. [Back]

135 Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 1994;70(2):363-70. [Back]

136 Hancock BW, Aitken M, Radstone C, Hudson GV. Why don’t cancer patients get entered into clinical trials? Experience of the Sheffield Lymphoma Group’s collaboration in British National Lymphoma Investigation studies. BMJ 1997;314(7073):36-7. [Back]

137 Ellis PM. Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Ann Oncol 2000;11(8):939-45. [Back]

138 Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”. J Clin Epidemiol 2001;54(3):217-24. [Back]

139 Dvoretsky PM, Richards KA, Angel C, Rabinowitz L, Beecham JB, Bonfiglio TA. Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer. Hum Path 1988,19(11):1273-9. [Back]

140 Rose PG, Piver MS, Tsukada Y, Lau TS. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 1989;64(7):1508-13. [Back]

141 Feuer DJ, Broadley KE. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. [Back] [section 8] [section 8.1]

142 Taylor RH. Laparotomy for obstruction with recurrent tumour. Br J Surg 1985;72:327. [Back]

143 Ketcham AS, Hoye RC, Pilch YH, Morton DL. Delayed intestinal obstruction following treatment for cancer. Cancer 1970;25(2):406-10. [Back]

144 Rubin SC, Hoskins WJ, Benjamin I, Lewis JL Jr. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol 1989;34(1):16-9. [Back]

145 van Ooijen B, van der Burg ME, Planting AS, Siersema PD, Wiggers T. Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet 1993;176(5):469-74. [Back]

146 Lau PW, Lorentz TG. Results of surgery for malignant bowel obstruction in advanced, unresectable, recurrent colorectal cancer. Dis Colon Rectum 1993;36(1):61-4. [Back]

147 Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant diasease. A clinical and pathological study. Lancet 1985;2(8462):990-3. [Back]

148 Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. [Back]

149 Twycross R, Wilcock A, Charlesworth S, Dickman A. Palliative care formulary. 2nd ed. Abingdon: Radcliffe Medical Press; 2002. [Back]

150 Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 2000;19(1):23-34. [Back]

151 Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 2000;8(3):188-91. [Back]

152 Bizer LS, Liebling RW, Delany HM, Gliedman ML. Small bowel obstruction: the role of nonoperative treatment in simple intestinal obstruction and predictive criteria for strangulation obstruction. Surgery 1981;89(4):407-13. [Back]

153 Koukouras D, Mastronikolis NS, Tzoracoleftherakis E, Angelopoulou E, Kalfarentzos F, Androulakis J. The role of nasogastric tube after elective abdominal surgery. Clin Ter 2001:152(4):241-4 [Back]

154 Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001;9(4):223-33. [Back]

155 Pelham A, Lee MA, Regnard CB. Gabapentin for coeliac plexus pain. Palliat Med 2002;16(4):355-6. [Back]

156 Scottish Intercollegiate Guidelines Network (SIGN). Control of pain in patients with cancer. Edinburgh: SIGN; 2000. (SIGN publication no. 44). [cited 4 Sep 2003]. Available from url: http://www.sign.ac.uk/guidelines/fulltext/44/index.html [Back]

157 General Medical Council. Tomorrow’s doctors. Recommendations on undergraduate medical education. London: The Council; 2002. [cited 4 Sep 2003]. Available from url: http://www.gmc-uk.org/med_ed/tomdoc.htm [Back]

158 Clinical Standards Board for Scotland. Clinical standards. Specialist palliative care. Revised ed. Edinburgh: The Board; 2002. [cited 4 Sep 2003]. Available from url: http://www.clinicalstandards.org/pdf/finalstand/SPC.pdf [Back]

159 Hearn J, Higginson IJ. Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review. Palliat Med 1998;12(5):317-32. [Back]

160 Addington-Hall JM, MacDonald LD, Anderson HR, Chamberlain J, Freeling P, Bland JM, et al. Randomised controlled trial of effects of coordinating care for terminally ill cancer patients. BMJ 1992;305(6865):1317-22. [Back]

161 Raftery JP, Addington-Hall JM, MacDonald LD, Anderson HR, Bland JM, Chamberlain J, et al. A randomized controlled trial of the cost-effectiveness of a district co-ordinating service for terminally ill cancer patients. Palliat Med 1996;10(2):151-61. [Back]

162 Jordhoy MS, Fayers P, Saltnes T, Ahlner-Elmqvist M, Jannert M, Kaasa S. A palliative-care intervention and death at home: a cluster randomised trial. Lancet 2000;356(9233):888-93. [Back]

163 Scottish Executive Health Department. Cancer in Scotland: action for change. Edinburgh: The Executive; 2001. [cited 4 Sep 2003]. Available from url: http://www.scotland.gov.uk/library3/health/csac-00.asp [Back]

164 University of York. NHS Centre for Reviews and Dissemination. Management of gynaecological cancers. Effective Health Care 1999;5(3). [cited 4 Sep 2003]. Available from url: http://www.york.ac.uk/inst/crd/ehc53.htm [Back]

165 Harris KA. The informational needs of patients with cancer and their families. Cancer Pract 1998;6(1):39-46. [Back]

166 Mohide EA, Whelan TJ, Rath D, Gafni A, Willan AR, Czukar D, et al. A randomised trial of two information packages distributed to new cancer patients before their initial appointment at a regional cancer centre. Br J Cancer 1996;73(12):1588-93. [Back]

167 Meredith C, Symonds P, Webster L, Lamont D, Pyper E, Gillis CR, et al. Information needs of cancer patients in west Scotland: cross sectional survey of patients’ views. BMJ 1996;313(7059):724-6. [Back]

168 Scott JT, Harmsen M, Prictor MJ, Entwistle VA, Sowden AJ, Watt I. Recordings or summaries of consultations for people with cancer (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. [Back]

169 Brown R, Butow PN, Boyer MJ, Tattersall MH. Promoting patient participation in the cancer consultation: evaluation of a prompt sheet and coaching in question-asking. Br J Cancer 1999;80(1-2):242-8. [Back]

170 Bruera E, Pituskin E, Calder K, Neumann CM, Hanson J. The addition of an audiocassette recording of a consultation to written recommendations for patients with advanced cancer: A randomized, controlled trial. Cancer 1999;86(11):2420-5. [Back]

171 Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993;50(9):681-9. [Back]

172 Hack TF, Pickles T, Bultz BD, Degner LF, Katz A, Davison BJ. Feasibility of an audiotape intervention for patients with cancer. A multicenter, randomized, controlled pilot study. J Psych Onc 1999;17(2):1-15. [Back]

173 Jones R, Pearson J, McGregor S, Cawsey AJ, Barrett A, Craig N, et al. Randomised trial of personalised computer based information for cancer patients. BMJ 1999;319(7219):1241-7. [Back]

174 McQuellon RP, Wells M, Hoffman S, Craven B, Russell G, Cruz J, et al. Reducing distress in cancer patients with an orientation program. Psychooncology 1998;7(3):207-17. [Back]

175 Walker LG, Walker MB, Ogston K, Heys SD, Ah-See AK, Miller ID, et al. Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Br J Cancer 1999;80(1-2):262-8. [Back]

176 Ong LM, Visser MR, Lammes FB, van Der Velden J, Kuenen BC, de Haes JC. Effect of providing cancer patients with the audiotaped initial consultation on satisfaction, recall, and quality of life: a randomized, double-blind study. J Clin Oncol 2000 ;18(16):3052-60. [Back]

177 University of York. NHS Centre for Reviews and Dissemination. Informing, communicating and sharing decisions with people who have cancer. Effective Health Care 2000;6(6). [cited 4 Sep 2003]. Available from url: http://www.york.ac.uk/inst/crd/ehc66.htm [Back]

178 Scottish Executive. Introduction of managed clinical networks within the NHS in Scotland. Edinburgh: The Executive; 1999. NHS MEL(1999)10. [cited 3 Sep 2003]. Available from url: http://www.show.scot.nhs.uk/sehd/mels/1999_10.htm [Back]

179 Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19(1):7-15. [Back]

180 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10. [Back]

181 Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995;27(3):219-26. [Back]

182 NHS Executive. Guidance on commissioning cancer services: improving outcomes in gynaecological cancer: the manual. London: The Executive; 1999. [cited 4 Sep 2003]. Available from url: http://www.dh.gov.uk/assetRoot/04/08/38/46/04083846.pdf [Back]

[Contents][Back][Top]

Home